|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
CN105601748B
(zh)
|
2011-07-01 |
2021-08-27 |
恩格姆生物制药公司 |
用于代谢病症和疾病治疗的组合物、应用和方法
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
SG11201500125QA
(en)
|
2012-07-11 |
2015-02-27 |
Blueprint Medicines Corp |
Inhibitors of the fibroblast growth factor receptor
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
HK1214832A1
(zh)
|
2012-11-28 |
2016-08-05 |
恩格姆生物制药公司 |
用於代謝病症和疾病治療的組合物和方法
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
ES2915851T3
(es)
|
2012-12-27 |
2022-06-27 |
Ngm Biopharmaceuticals Inc |
Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
EP3943087A1
(en)
|
2013-03-15 |
2022-01-26 |
Celgene CAR LLC |
Heteroaryl compounds and uses thereof
|
|
US9321786B2
(en)
|
2013-03-15 |
2016-04-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
|
CN105307657B
(zh)
|
2013-03-15 |
2020-07-10 |
西建卡尔有限责任公司 |
杂芳基化合物和其用途
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US9783504B2
(en)
|
2013-07-09 |
2017-10-10 |
Dana-Farber Cancer Institute, Inc. |
Kinase inhibitors for the treatment of disease
|
|
BR112016005199B1
(pt)
|
2013-08-23 |
2022-02-22 |
Neupharma, Inc |
Certos compostos químicos, composições, e métodos
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
SI3057969T1
(sl)
|
2013-10-17 |
2018-10-30 |
Blueprint Medicines Corporation |
Sestavki, uporabni za zdravljenje motenj, povezanih s KIT
|
|
PH12016500676B1
(en)
|
2013-10-18 |
2022-07-20 |
Eisai R&D Man Co Ltd |
Pyrimidine fgfr4 inhibitors
|
|
TN2016000115A1
(en)
|
2013-10-25 |
2017-07-05 |
Novartis Ag |
Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
|
|
RS63405B1
(sr)
|
2013-10-25 |
2022-08-31 |
Blueprint Medicines Corp |
Inhibitori receptora faktora rasta fibroblasta
|
|
CA2927592C
(en)
|
2013-10-28 |
2020-08-18 |
Ngm Biopharmaceuticals, Inc. |
Fgf-19 variants for treating a fgf-19 dependent cancer or tumor
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
JP6387111B2
(ja)
|
2014-01-20 |
2018-09-05 |
クリーブ バイオサイエンシズ インコーポレイテッド |
ｐ９７複合体の阻害剤としての縮合ピリミジン
|
|
PE20170256A1
(es)
|
2014-01-24 |
2017-04-22 |
Ngm Biopharmaceuticals Inc |
Proteinas de union y sus metodos de uso
|
|
PT3102577T
(pt)
*
|
2014-02-07 |
2018-10-23 |
Principia Biopharma Inc |
Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos
|
|
WO2015134210A1
(en)
|
2014-03-03 |
2015-09-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
|
WO2015183890A2
(en)
|
2014-05-28 |
2015-12-03 |
Ngm Biopharmaceuticals, Inc. |
Methods and compositions for the treatment of metabolic disorders and diseases
|
|
AU2015277438B2
(en)
|
2014-06-16 |
2020-02-27 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN105017227B
(zh)
*
|
2014-07-08 |
2018-03-09 |
四川百利药业有限责任公司 |
N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
|
|
KR102344105B1
(ko)
|
2014-08-18 |
2021-12-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
모노시클릭 피리딘 유도체의 염 및 이의 결정
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP6585167B2
(ja)
|
2014-10-03 |
2019-10-02 |
ノバルティス アーゲー |
Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
RU2729161C2
(ru)
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2016115412A1
(en)
*
|
2015-01-18 |
2016-07-21 |
Newave Pharmaceutical Llc |
Dual-warhead covalent inhibitors of fgfr-4
|
|
WO2016127074A1
(en)
|
2015-02-06 |
2016-08-11 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
|
|
EP3270694A4
(en)
*
|
2015-02-17 |
2018-09-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
MA41551A
(fr)
*
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
EP3275442B1
(en)
|
2015-03-25 |
2021-07-28 |
National Cancer Center |
Therapeutic agent for bile duct cancer
|
|
AU2016238436A1
(en)
|
2015-03-25 |
2017-08-17 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
|
US9802917B2
(en)
|
2015-03-25 |
2017-10-31 |
Novartis Ag |
Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
KR102548229B1
(ko)
|
2015-04-14 |
2023-06-27 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
결정질 fgfr4 억제제 화합물 및 그의 용도
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
EP3298011B1
(en)
*
|
2015-05-22 |
2021-11-17 |
Principia Biopharma Inc. |
Quinolone derivatives as fibroblast growth factor receptor inhibitors
|
|
UA124090C2
(uk)
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
BR112018000808A2
(pt)
|
2015-07-16 |
2018-09-04 |
Array Biopharma Inc |
compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
CN108026102A
(zh)
|
2015-07-24 |
2018-05-11 |
蓝印药品公司 |
可用于治疗与kit和pdgfr相关的病症的化合物
|
|
US10800843B2
(en)
|
2015-07-29 |
2020-10-13 |
Ngm Biopharmaceuticals, Inc. |
Beta klotho-binding proteins
|
|
AU2016304852B2
(en)
*
|
2015-08-11 |
2020-12-10 |
Principia Biopharma, Inc. |
Processes for preparing an FGFR inhibitor
|
|
BR112018003588A2
(pt)
|
2015-08-26 |
2018-09-25 |
Blueprint Medicines Corp |
compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
US10208024B2
(en)
|
2015-10-23 |
2019-02-19 |
Array Biopharma Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
|
|
EP3368039A1
(en)
|
2015-10-26 |
2018-09-05 |
The Regents of The University of Colorado, A Body Corporate |
Point mutations in trk inhibitor-resistant cancer and methods relating to the same
|
|
SI3371171T1
(sl)
|
2015-11-02 |
2024-03-29 |
Blueprint Medicines Corporation |
Inhibitorji ret
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
SG10201912607SA
(en)
|
2015-11-19 |
2020-02-27 |
Blueprint Medicines Corp |
Compounds and compositions useful for treating disorders related to ntrk
|
|
CN108367000A
(zh)
|
2015-12-17 |
2018-08-03 |
卫材R&D管理有限公司 |
用于乳腺癌的治疗剂
|
|
CN105669566A
(zh)
*
|
2016-03-09 |
2016-06-15 |
华东师范大学 |
一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法
|
|
US10183928B2
(en)
|
2016-03-17 |
2019-01-22 |
Blueprint Medicines Corporation |
Inhibitors of RET
|
|
AU2017246547B2
(en)
|
2016-04-04 |
2023-02-23 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
FI3439662T3
(fi)
|
2016-04-04 |
2024-09-04 |
Loxo Oncology Inc |
(s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
CN109311889B
(zh)
|
2016-04-15 |
2021-11-16 |
缆图药品公司 |
激活素受体样激酶抑制剂
|
|
JP7372740B2
(ja)
|
2016-05-10 |
2023-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
|
|
EP3458456B1
(en)
|
2016-05-18 |
2020-11-25 |
Loxo Oncology Inc. |
Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
|
|
KR20180002053A
(ko)
*
|
2016-06-28 |
2018-01-05 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
WO2018004258A1
(ko)
*
|
2016-06-28 |
2018-01-04 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
WO2018022761A1
(en)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Substituted cyclopentane-amides for treating disorders related to ret
|
|
WO2018035061A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CA3034399A1
(en)
|
2016-08-26 |
2018-03-01 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
CN107793395B
(zh)
*
|
2016-09-01 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂及其用途
|
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
WO2018072707A1
(zh)
*
|
2016-10-18 |
2018-04-26 |
保诺科技（北京）有限公司 |
芳香族醚类衍生物、其制备方法及其在医药上的应用
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
SG11201903911UA
(en)
|
2016-11-02 |
2019-05-30 |
Novartis Ag |
Combinations of fgfr4 inhibitors and bile acid sequestrants
|
|
CA3043948C
(en)
*
|
2016-11-17 |
2021-08-31 |
Guangdong Zhongsheng Pharmaceutical Co., Ltd |
Fgfr4 inhibitor and preparation method and use thereof
|
|
KR101812266B1
(ko)
|
2016-11-25 |
2017-12-27 |
한국과학기술연구원 |
4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
|
|
AU2017378943B2
(en)
*
|
2016-12-19 |
2020-06-18 |
Abbisko Therapeutics Co., Ltd. |
FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
|
|
CN108239069B
(zh)
*
|
2016-12-26 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
一种用于成纤维细胞生长因子受体的抑制剂及其用途
|
|
CN108264511B
(zh)
*
|
2017-01-03 |
2021-04-13 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和其在医药上的用途
|
|
WO2018136661A1
(en)
|
2017-01-18 |
2018-07-26 |
Andrews Steven W |
SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
CN108503593B
(zh)
*
|
2017-02-28 |
2021-04-27 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
US11040979B2
(en)
|
2017-03-31 |
2021-06-22 |
Blueprint Medicines Corporation |
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
|
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
|
US10745385B2
(en)
|
2017-05-25 |
2020-08-18 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
CN110869357A
(zh)
|
2017-05-25 |
2020-03-06 |
亚瑞克西斯制药公司 |
化合物及其用于治疗癌症的使用方法
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
CA3074885A1
(en)
*
|
2017-09-05 |
2019-03-14 |
Bioardis Llc |
Aromatic derivative, preparation method for same, and medical applications thereof
|
|
TWI876442B
(zh)
|
2017-10-10 |
2025-03-11 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
KR102717072B1
(ko)
|
2017-10-18 |
2024-10-15 |
인사이트 코포레이션 |
Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
|
|
EP3697786B1
(en)
|
2017-10-18 |
2022-08-31 |
Blueprint Medicines Corporation |
Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
|
|
KR20190043437A
(ko)
|
2017-10-18 |
2019-04-26 |
씨제이헬스케어 주식회사 |
단백질 키나제 억제제로서의 헤테로고리 화합물
|
|
WO2019085894A1
(zh)
*
|
2017-10-30 |
2019-05-09 |
如东凌达生物医药科技有限公司 |
一类含氮稠环化合物及其制备方法和用途
|
|
EP3740490A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
|
|
JP7060694B2
(ja)
|
2018-01-18 |
2022-04-26 |
アレイ バイオファーマ インコーポレイテッド |
Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物
|
|
US11472802B2
(en)
|
2018-01-18 |
2022-10-18 |
Array Biopharma Inc. |
Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
|
|
JP7168149B2
(ja)
|
2018-02-08 |
2022-11-09 |
▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 |
Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
|
|
US11219619B2
(en)
|
2018-03-28 |
2022-01-11 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for hepatocellular carcinoma
|
|
PE20210096A1
(es)
|
2018-04-03 |
2021-01-12 |
Blueprint Medicines Corp |
Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
|
|
CN110386921A
(zh)
*
|
2018-04-23 |
2019-10-29 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂化合物
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
CN111868058B
(zh)
*
|
2018-05-25 |
2023-06-13 |
上海和誉生物医药科技有限公司 |
一种fgfr抑制剂、其制备方法和在药学上的应用
|
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
|
CN112313207B
(zh)
*
|
2018-06-22 |
2023-02-14 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
CN117285467A
(zh)
|
2018-07-31 |
2023-12-26 |
罗索肿瘤学公司 |
喷雾干燥的分散体和制剂
|
|
MX2021000887A
(es)
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
CN112996794A
(zh)
|
2018-09-10 |
2021-06-18 |
阿雷生物药品公司 |
作为ret激酶抑制剂的稠合杂环化合物
|
|
US12351576B2
(en)
|
2018-09-14 |
2025-07-08 |
Abbisko Therapeutics Co., Ltd. |
FGFR inhibitor, preparation method therefor and application thereof
|
|
CN110950867A
(zh)
*
|
2018-09-27 |
2020-04-03 |
首药控股(北京)有限公司 |
一种fgfr4激酶抑制剂及其制备方法和用途
|
|
CN111138459B
(zh)
*
|
2018-11-06 |
2022-10-18 |
南京圣和药业股份有限公司 |
Fgfr4抑制剂的光学异构体及其应用
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020119606A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of fibroblast growth factor receptor
|
|
US12351571B2
(en)
|
2018-12-19 |
2025-07-08 |
Array Biopharma Inc. |
Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases
|
|
EP3898626A1
(en)
*
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
WO2020177067A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Bioardis Llc |
Aromatic derivatives, preparation methods, and medical uses thereof
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US20220185811A1
(en)
*
|
2019-03-08 |
2022-06-16 |
Shouyao Holdings (beijing) Co., Ltd. |
Fgfr4 kinase inhibitor and preparation method therefor and use thereof
|
|
ES2966512T3
(es)
|
2019-04-12 |
2024-04-22 |
Blueprint Medicines Corp |
Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración
|
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4006027B1
(en)
|
2019-07-26 |
2025-10-01 |
CGeneTech (Suzhou, China) Co., Ltd. |
Pyridine derivative as fgfr and vegfr dual inhibitors for the treatment of cancer
|
|
CN114174272B
(zh)
*
|
2019-08-08 |
2023-05-12 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的制备方法
|
|
ES2954774T3
(es)
*
|
2019-08-08 |
2023-11-24 |
Zhangzhou Pien Tze Huang Pharm |
Forma cristalina A y forma cristalina B del compuesto de pirazina-2(1H)-cetona y su método de preparación
|
|
CN114269723B
(zh)
*
|
2019-08-08 |
2023-09-12 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN112759593A
(zh)
|
2019-11-01 |
2021-05-07 |
北京伯汇生物技术有限公司 |
桥环并醛基吡啶衍生物及其应用
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US20230101747A1
(en)
|
2019-12-06 |
2023-03-30 |
Schrödinger, Inc. |
Cyclic compounds and methods of using same
|
|
KR102797616B1
(ko)
*
|
2019-12-23 |
2025-04-21 |
베이징 사이텍-엠큐 파마슈티컬즈 리미티드 |
시아노-치환된 피리딘 및 시아노-치환된 피리미딘 화합물 및 이의 제조방법 및 이의 적용
|
|
IL294214B2
(en)
|
2019-12-27 |
2026-04-01 |
Schrodinger Inc |
Cyclic compounds and methods for using them
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4157829A1
(en)
|
2020-05-29 |
2023-04-05 |
Blueprint Medicines Corporation |
Solid forms of pralsetinib
|
|
CN116096707A
(zh)
*
|
2020-06-05 |
2023-05-09 |
金耐特生物制药公司 |
成纤维细胞生长因子受体激酶的抑制剂
|
|
CN116490507A
(zh)
|
2020-09-10 |
2023-07-25 |
薛定谔公司 |
用于治疗癌症的杂环包缩合cdc7激酶抑制剂
|
|
CN112851587A
(zh)
*
|
2021-01-21 |
2021-05-28 |
药雅科技(上海)有限公司 |
一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
|
|
CA3206502A1
(en)
*
|
2021-01-26 |
2022-08-04 |
Zhengxia CHEN |
Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method therefor
|
|
EP4284804A1
(en)
|
2021-01-26 |
2023-12-06 |
Schrödinger, Inc. |
Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
|
|
CN114853740B
(zh)
*
|
2021-02-03 |
2023-08-01 |
药雅科技(上海)有限公司 |
炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途
|
|
TWI820622B
(zh)
*
|
2021-03-04 |
2023-11-01 |
美商美國禮來大藥廠 |
Fgfr3抑制劑化合物
|
|
WO2022194160A1
(zh)
*
|
2021-03-16 |
2022-09-22 |
上海启晟合研医药科技有限公司 |
非索替尼固体形式及其制备方法
|
|
TW202300150A
(zh)
|
2021-03-18 |
2023-01-01 |
美商薛定諤公司 |
環狀化合物及其使用方法
|
|
EP4317143A4
(en)
*
|
2021-03-26 |
2025-01-15 |
Hangzhou Apeloa Medicine Research Institute Co., Ltd. |
BICYCLIC HETEROCYCLIC FGFR4 INHIBITOR, PHARMACEUTICAL COMPOSITION AND PREPARATION THEREOF AND USE THEREOF
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN113912602B
(zh)
*
|
2021-10-14 |
2023-05-05 |
温州医科大学 |
一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
|
|
EP4722212A1
(en)
*
|
2023-05-25 |
2026-04-08 |
Magicbullettherapeutics Co., Ltd. |
Novel compound for inhibiting protein kinases and pharmaceutical composition comprising same
|
|
TWI896159B
(zh)
*
|
2023-06-09 |
2025-09-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
WO2025059027A1
(en)
|
2023-09-11 |
2025-03-20 |
Schrödinger, Inc. |
Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
|